Aberrant lipid metabolism as a therapeutic target in liver cancer

References

• Ananthakrishnan A, Gogineni V, Saeian K. Epidemiology of primary and secondary liver cancers. Semin Intervent Radiol. 2006;23(1):47–63.
   PubMedGoogle Scholar
• Balogh J, Victor D, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016 Oct 05;3:41–53.
   PubMed Web of Science ®Google Scholar
• McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011 May;15(2):223–43, vii-x.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018 July 05;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017 Jun 24;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Bechmann LP, Hannivoort RA, Gerken G, et al. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012 Apr 01;56(4):952–964.
   PubMed Web of Science ®Google Scholar
• Bauer DE, Hatzivassiliou G, Zhao F, et al. ATP citrate lyase is an important component of cell growth and transformation. Oncogene. 2005 Sep 15;24(41):6314–6322.
   PubMed Web of Science ®Google Scholar
• Litwack G. Chapter 9 - lipids. In: Litwack G, editor. Human biochemistry. Boston: Academic Press; 2018. p. 199–255.
   Google Scholar
• Miyazaki M, Kim HJ, Man WC, et al. Oleoyl-CoA is the major de novo product of stearoyl-CoA desaturase 1 gene isoform and substrate for the biosynthesis of the Harderian gland 1-alkyl-2,3-diacylglycerol. J Biol Chem. 2001 Oct 19;276(42):39455–39461.
   PubMed Web of Science ®Google Scholar
• Semenkovich CF, Goldberg AC, Goldberg IJ. Chapter 37 - disorders of lipid metabolism. In: Melmed S, Polonsky KS, Larsen PR, et al., editors. Williams textbook of endocrinology. 13 ed. Philadelphia: Content Repository Only!; 2016. p. 1660–1700.
   Google Scholar
• Santos CR, Schulze A. Lipid metabolism in cancer. Febs J. 2012 Aug;279(15):2610–2623.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007 Oct 01 online;7:763.
   PubMed Web of Science ®Google Scholar
• Abramson HN. The lipogenesis pathway as a cancer target. J Med Chem. 2011 Aug 25;54(16):5615–5638.
   PubMed Web of Science ®Google Scholar
• Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. Trends Cell Biol. 2014 Aug;24(8):472–478.
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Marlow LA, Wei JJ, et al. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013 May 1;19(9):2368–2380.
   PubMed Web of Science ®Google Scholar
• Muir K, Hazim A, He Y, et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 2013 Aug 1;73(15):4722–4731.
   PubMed Web of Science ®Google Scholar
• Nelson GM, Ahlborn GJ, Allen JW, et al. Transcriptional changes associated with reduced spontaneous liver tumor incidence in mice chronically exposed to high dose arsenic. Toxicology. 2009 Dec 21;266(1–3):6–15.
   PubMed Web of Science ®Google Scholar
• Falvella FS, Pascale RM, Gariboldi M, et al. Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis. 2002 Nov;23(11):1933–1936.
   PubMed Web of Science ®Google Scholar
• Watson JA, Fang M, Lowenstein JM. Tricarballylate and hydroxycitrate: substrate and inhibitor of ATP: citrate oxaloacetate lyase. Arch Biochem Biophys. 1969 Dec;135(1):209–217.
   PubMed Web of Science ®Google Scholar
• Verschueren KHG, Blanchet C, Felix J, et al. Structure of ATP citrate lyase and the origin of citrate synthase in the Krebs cycle. Nature. 2019 Apr;568(7753):571-575.
   PubMed Web of Science ®Google Scholar
• Zaidi N, Swinnen JV, Smans K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res. 2012 Aug 1;72(15):3709–3714.
   PubMed Web of Science ®Google Scholar
• Wei J, Leit S, Kuai J, et al. An allosteric mechanism for potent inhibition of human ATP-citrate lyase. Nature. 2019 Apr;568(7753):566-570.
   Web of Science ®Google Scholar
• Yahagi N, Shimano H, Hasegawa K, et al. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer. 2005 Jun;41(9):1316–1322.
   PubMed Web of Science ®Google Scholar
• Migita T, Narita T, Nomura K, et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 2008 Oct 15;68(20):8547–8554.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Bollu LR, Tozzi F, et al. ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Mol Cancer Ther. 2013 Dec;12(12):2782–2791.
   PubMed Web of Science ®Google Scholar
• Teng L, Chen Y, Cao Y, et al. Overexpression of ATP citrate lyase in renal cell carcinoma tissues and its effect on the human renal carcinoma cells in vitro. Oncol Lett. 2018 May;15(5):6967–6974.
   PubMed Web of Science ®Google Scholar
• Beckner ME, Fellows-Mayle W, Zhang Z, et al. Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas. Int J Cancer. 2010 May 15;126(10):2282–2295.
   PubMed Web of Science ®Google Scholar
• Carrer A, Trefely S, Zhao S, et al. Acetyl-CoA metabolism supports multistep pancreatic tumorigenesis. Cancer Discov. 2019 Mar;9(3):416–435.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ray KK, Catapano AL, et al. Mendelian randomization study of ACLY and cardiovascular disease. N Engl J Med. 2019 Mar 14;380(11):1033–1042.
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Zhao F, Bauer DE, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005 Oct;8(4):311–321.
   PubMed Web of Science ®Google Scholar
• Zaidi N, Royaux I, Swinnen JV, et al. ATP citrate lyase knockdown induces growth arrest and apoptosis through different cell- and environment-dependent mechanisms. Mol Cancer Ther. 2012 Sep;11(9):1925–1935.
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hatzivassiliou G, Sachdeva UM, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science (New York, NY). 2009 May 22;324(5930):1076–1080.
   Google Scholar
• Hanai JI, Doro N, Seth P, et al. ATP citrate lyase knockdown impacts cancer stem cells in vitro. Cell Death Dis. 2013 Jun;27(4):e696.
   Google Scholar
• Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol. 2014 Aug;25(4):309–315.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134–151.
   PubMed Web of Science ®Google Scholar
• Rose-Kahn G, Bar-Tana J. Inhibition of rat liver acetyl-CoA carboxylase by beta, beta’-tetramethyl-substituted hexadecanedioic acid (MEDICA 16). Biochim Biophys Acta. 1990 Feb 6;1042(2):259–264.
   PubMedGoogle Scholar
• Gutierrez MJ, Rosenberg NL, Macdougall DE, et al. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676–683.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Raya JL, et al. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: results of the GRAVITY randomized study. Atherosclerosis. 2014 Jan;232(1):86–93.
   PubMed Web of Science ®Google Scholar
• Lemus HN, Mendivil CO. Adenosine triphosphate citrate lyase: emerging target in the treatment of dyslipidemia. J Clin Lipidol. 2015 May-Jun;9(3): 384–389.
   PubMed Web of Science ®Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019 Mar 14;380(11):1022–1032.
   PubMed Web of Science ®Google Scholar
• Berkhout TA, Havekes LM, Pearce NJ, et al. The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2. Biochem J. 1990 Nov 15;272(1):181–186.
   PubMed Web of Science ®Google Scholar
• Schwartz L, Abolhassani M, Guais A, et al. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol Rep. 2010 May;23(5):1407–1416.
   PubMed Web of Science ®Google Scholar
• Guais A, Baronzio G, Sanders E, et al. Adding a combination of hydroxycitrate and lipoic acid (METABLOC) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs. 2012 Feb;30(1):200–211.
   PubMed Web of Science ®Google Scholar
• Gao Y, Islam MS, Tian J, et al. Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth. Cancer Lett. 2014 Jul 10;349(1):15–25.
   PubMed Web of Science ®Google Scholar
• Jernigan FE, Hanai JI, Sukhatme VP, et al. Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening. Bioorg Med Chem Lett. 2017 Feb 15;27(4):929–935.
   PubMed Web of Science ®Google Scholar
• Koerner SK, Hanai JI, Bai S, et al. Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase. Eur J Med Chem. 2017 Jan 27;126:920–928.
   PubMed Web of Science ®Google Scholar
• Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 2010;31(9):1509–1515.
   PubMed Web of Science ®Google Scholar
• Ntambi JM. Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res. 1999 Sep;40(9):1549–1558.
   PubMed Web of Science ®Google Scholar
• Liu X, Strable MS, Ntambi JM. Stearoyl CoA desaturase 1: role in cellular inflammation and stress. Adv Nutr. 2011 Jan;2(1):15–22.
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Marlow LA, Pinkerton AB, et al. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. J Clin Endocrinol Metab. 2015 May;100(5):E697–709.
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Copland JA. Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma. Expert Opin Ther Targets. 2016 Feb 01;20(2):159–166.
   PubMed Web of Science ®Google Scholar
• Ma MKF, Lau EYT, Leung DHW, et al. Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. J Hepatol. 2017 Nov;67(5):979–990.
   PubMed Web of Science ®Google Scholar
• Bansal S, Berk M, Alkhouri N, et al. Stearoyl-CoA desaturase plays an important role in proliferation and chemoresistance in human hepatocellular carcinoma. J Surg Res. 2014 Jan;186(1):29–38.
   PubMed Web of Science ®Google Scholar
• Miyazaki M, Flowers MT, Sampath H, et al. Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis. Cell Metab. 2007 Dec;6(6):484–496.
   PubMed Web of Science ®Google Scholar
• Ntambi JM, Miyazaki M. Recent insights into stearoyl-CoA desaturase-1. Curr Opin Lipidol. 2003 Jun;14(3):255–261.
   PubMed Web of Science ®Google Scholar
• Pharmacokinetics and pharmacodynamics of MK-8245 in participants with type 2 diabetes (MK-8245-012). [Cited 2019 Apr 9]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00972322
   Google Scholar
• Zhang Z, Dales NA, Winther MD. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease. J Med Chem. 2014 Jun 26;57(12):5039–5056.
   PubMed Web of Science ®Google Scholar
• Koltun DO, Parkhill EQ, Vasilevich NI, et al. Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2048–2052.
   PubMed Web of Science ®Google Scholar
• Sun S, Zhang Z, Raina V, et al. Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects. Bioorg Med Chem Lett. 2014 Jan 15;24(2):526–531.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos PC, Gonzales SS, Winterton SE, et al. Discovery of tumor-specific irreversible inhibitors of stearoyl CoA desaturase. Nat Chem Biol. 2016 Feb 01 online;12:218.
   PubMed Web of Science ®Google Scholar
• von Roemeling CA, Caulfield TR, Marlow L, et al. Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget. 2018 Jan 2;9(1):3–20.
   PubMedGoogle Scholar
• Fritz V, Benfodda Z, Rodier G, et al. Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther. 2010 Jun;9(6):1740–1754.
   PubMed Web of Science ®Google Scholar
• Li W, Bai H, Liu S, et al. Targeting stearoyl-CoA desaturase 1 to repress endometrial cancer progression. Oncotarget. 2018 Feb 23;9(15):12064–12078.
   PubMedGoogle Scholar
• Lee S, Zhang C, Liu Z, et al. Network analyses identify liver-specific targets for treating liver diseases. Mol Syst Biol. 2017 Aug 21;13(8):938.
   PubMed Web of Science ®Google Scholar
• Buckley D, Duke G, Heuer TS, et al. Fatty acid synthase - Modern tumor cell biology insights into a classical oncology target. Pharmacol Ther. 2017;177:23–31.
   PubMed Web of Science ®Google Scholar
• Zhou W, Simpson PJ, McFadden JM, et al. Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells. Cancer Res. 2003 Nov 1;63(21):7330–7337.
   PubMed Web of Science ®Google Scholar
• Hardwicke MA, Rendina AR, Williams SP, et al. A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774–779.
   PubMed Web of Science ®Google Scholar
• Flavin R, Peluso S, Nguyen PL, et al. Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010 Apr;6(4):551–562.
   PubMed Web of Science ®Google Scholar
• Alwarawrah Y, Hughes P, Loiselle D, et al. Fasnall, a selective FASN inhibitor, shows potent anti-tumor activity in the MMTV-neu model of HER2(+) breast cancer. Cell Chem Biol. 2016 Jun 23;23(6):678–688.
   PubMed Web of Science ®Google Scholar
• Duke G, Wagman AS, Buckley D, et al. LBP-515 - Establishing the foundation for a novel, first-in-class, fatty acid synthase inhibitor, TVB-2640, for the treatment of NASH. J Hepatol. 2017 Jan 01;66(1, Supplement):S99–S100.
   Web of Science ®Google Scholar
• Falchook G, Patel M, Infante J, et al. Abstract CT153: first in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640. Cancer Res. 2017;77(13Supplement):CT153.
   Google Scholar
• FASN inhibitor TVB-2640, paclitaxel, and trastuzumab in treating patients with HER2 positive advanced breast cancer. [Cited 2019 Apr 9]. Available from: https://ClinicalTrials.gov/show/NCT03179904
   Google Scholar
• TVB 2640 for resectable colon cancer other resectable cancers; a window trial. [Cited 2019 Apr 9]. Available from: https://ClinicalTrials.gov/show/NCT02980029
   Google Scholar
• TVB- 2640 in combination with bevacizumab in patients with first relapse of high grade astrocytoma. [Cited 2019 Apr 9]. Available from: https://ClinicalTrials.gov/show/NCT03032484
   Google Scholar
• Wakil SJ, Abu-Elheiga LA. Fatty acid metabolism: target for metabolic syndrome. J Lipid Res. 2009 Apr;50(Suppl):S138–43.
   PubMedGoogle Scholar
• Chow JD, Lawrence RT, Healy ME, et al. Genetic inhibition of hepatic acetyl-CoA carboxylase activity increases liver fat and alters global protein acetylation. Mol Metab. 2014 Jul;3(4):419–431.
   PubMed Web of Science ®Google Scholar
• Abu-Elheiga L, Almarza-Ortega DB, Baldini A, et al. Human acetyl-CoA carboxylase 2. Molecular cloning, characterization, chromosomal mapping, and evidence for two isoforms. J Biol Chem. 1997 Apr 18;272(16):10669–10677.
   PubMed Web of Science ®Google Scholar
• Wang C, Rajput S, Watabe K, et al. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci (Schol Ed). 2010 Jan 1;2:515–526.
   PubMedGoogle Scholar
• Wei Q, Mei L, Yang Y, et al. Design, synthesis and biological evaluation of novel spiro-pentacylamides as acetyl-CoA carboxylase inhibitors. Bioorg Med Chem. 2018 Aug 7;26(14):3866–3874.
   PubMed Web of Science ®Google Scholar
• Jones JEC, Esler WP, Patel R, et al. Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) reduces proliferation and de novo lipogenesis of EGFRvIII human glioblastoma cells. PloS One. 2017;12(1):e0169566.
   PubMed Web of Science ®Google Scholar
• Svensson RU, Parker SJ, Eichner LJ, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small cell lung cancer in preclinical models. Nat Med. 2016 Sep 19;22(10):1108–1119.
   PubMed Web of Science ®Google Scholar
• Sugimoto Y, Naniwa Y, Nakamura T, et al. A novel acetyl-CoA carboxylase inhibitor reduces de novo fatty acid synthesis in HepG2 cells and rat primary hepatocytes. Arch Biochem Biophys. 2007 Dec 1;468(1):44–48.
   PubMed Web of Science ®Google Scholar
• Calvisi DF, Wang C, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011 Mar;140(3):1071–1083.
   PubMed Web of Science ®Google Scholar
• Wang MD, Wu H, Huang S, et al. HBx regulates fatty acid oxidation to promote hepatocellular carcinoma survival during metabolic stress. Oncotarget. 2016 Feb 9;7(6):6711–6726.
   PubMedGoogle Scholar
• Wei L, Harriman G, Ghoshal S, et al. Abstract 3781: combination therapy with a liver selective acetyl-CoA carboxylase inhibitor ND-654 and sorafenib improves efficacy in the treatment of cirrhotic rats with hepatocellular carcinoma. Cancer Res. 2016;76(14 Supplement):3781.
   Google Scholar
• Lally JSV, Ghoshal S, DePeralta DK, et al. Inhibition of Acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019 Jan 8;29(1):174–82.e5.
   PubMed Web of Science ®Google Scholar
• Rios Garcia M, Steinbauer B, Srivastava K, et al. Acetyl-CoA carboxylase 1-dependent protein acetylation controls breast cancer metastasis and recurrence. Cell Metab. 2017 Dec 5;26(6):842–55.e5.
   PubMed Web of Science ®Google Scholar
• Muramatsu T. Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. J Biochem. 2016 May;159(5):481–490.
   PubMed Web of Science ®Google Scholar
• Lee A, Rode A, Nicoll A, et al. Circulating CD147 predicts mortality in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2016;31(2):459–466.
   PubMed Web of Science ®Google Scholar
• Li J, Huang Q, Long X, et al. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARalpha pathways. J Hepatol. 2015 Dec;63(6):1378–1389.
   PubMed Web of Science ®Google Scholar
• Niu H, Wang R, Cheng J, et al. Treatment of (131)I-labeled anti-CD147 monoclonal antibody in VX2 carcinoma-induced liver tumors. Oncol Rep. 2013 Jul;30(1):246–252.
   PubMed Web of Science ®Google Scholar
• Bian H, Zheng JS, Nan G, et al. Randomized trial of [131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation. J Natl Cancer Inst. 2014 Sep;106(9).
   PubMedGoogle Scholar
• Yang X, Zhang D, Liu S, et al. KLF4 suppresses the migration of hepatocellular carcinoma by transcriptionally upregulating monoglyceride lipase. Am J Cancer Res. 2018;8(6):1019–1029.
   PubMed Web of Science ®Google Scholar
• Sun H, Tang H, Xie D, et al. Krüppel-like factor 4 blocks hepatocellular carcinoma dedifferentiation and progression through activation of hepatocyte nuclear factor-6. Clin Cancer Res off J Am Assoc Cancer Res. 2016 Sep 02;22(2):502–512.
   PubMed Web of Science ®Google Scholar
• Tian X, Dai S, Sun J, et al. F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression. Oncotarget. 2015 May 28;6(26):22767–22775.
   PubMedGoogle Scholar
• Lehner F, Kulik U, Klempnauer J, et al. Inhibition of the liver enriched protein FOXA2 recovers HNF6 activity in human colon carcinoma and liver hepatoma cells. PloS One. 2010 Oct 13;5(10):e13344.
   PubMed Web of Science ®Google Scholar
• Fowler CJ. Monoacylglycerol lipase – a target for drug development? Br J Pharmacol. 2012 Nov 30;166(5):1568–1585.
   PubMed Web of Science ®Google Scholar
• Mulvihill MM, Nomura DK. Therapeutic potential of monoacylglycerol lipase inhibitors. Life Sci. 2013 Nov 08;92(8–9):492–497.
   PubMed Web of Science ®Google Scholar
• Ye L, Zhang B, Seviour EG, et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett. 2011 Aug 1;307(1):6–17.
   PubMed Web of Science ®Google Scholar
• Nomura DK, Lombardi DP, Chang JW, et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol. 2011 Jul 29;18(7):846–856.
   PubMedGoogle Scholar
• Kopp F, Komatsu T, Nomura DK, et al. The glycerophospho metabolome and its influence on amino acid homeostasis revealed by brain metabolomics of GDE1(-/-) mice. Chem Biol. 2010 Aug 27;17(8):831–840.
   PubMedGoogle Scholar
• Jeon S-M. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016 Jul 15;48(7):e245.
   PubMed Web of Science ®Google Scholar
• Li Y, Xu S, Mihaylova MM, et al. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab. 2011 Apr 6;13(4):376–388.
   PubMed Web of Science ®Google Scholar
• Hardie DG, Pan DA. Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase. Biochem Soc Trans. 2002 Nov;30(Pt 6):1064–1070.
   PubMed Web of Science ®Google Scholar
• Carling D, Clarke PR, Zammit VA, et al. Purification and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem. 1989 Dec 8;186(1–2):129–136.
   PubMedGoogle Scholar
• Muoio DM, Seefeld K, Witters LA, et al. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem J. 1999 Mar 15;338(Pt 3):783–791.
   PubMedGoogle Scholar
• Cheng J, Huang T, Li Y, et al. AMP-activated protein kinase suppresses the In Vitro and In Vivo proliferation of hepatocellular carcinoma. PloS One. 2014 Apr 07;9(4):e93256.
   PubMed Web of Science ®Google Scholar
• Hsieh FS, Chen YL, Hung MH, et al. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner. Mol Oncol. 2017 Aug;11(8):1035–1049.
   PubMed Web of Science ®Google Scholar
• Wang ST, Ho HJ, Lin JT, et al. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells. Cell Death Dis. 2017 Feb 23;8(2):e2626.
   PubMed Web of Science ®Google Scholar
• Sun Y, Tao C, Huang X, et al. Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway. Onco Targets Ther. 2016;9:2845–2853.
   PubMed Web of Science ®Google Scholar
• Koyama S, Akbay EA, Li YY, et al. STK11/LKB1 Deficiency promotes neutrophil recruitment and proinflammatory cytokine production to suppress T-cell activity in the lung tumor microenvironment. Cancer Res. 2016 Mar 1;76(5):999–1008.
   PubMed Web of Science ®Google Scholar
• Roemeling CAEV, Caulfield T, Qie Y, et al. Abstract LB-189: blockade of stearoyl CoA desaturase 1 promotes immunogenic clearance of tumors. Cancer Res. 2017;77(13 Supplement):LB–189.
   Google Scholar
• Zhang F, Du G. Dysregulated lipid metabolism in cancer. World J Biol Chem. 2012 Aug 26;3(8):167–174.
   PubMedGoogle Scholar
• Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013 Mar 7;4:e532.
   PubMed Web of Science ®Google Scholar
• Beckers A, Organe S, Timmermans L, et al. Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells. Cancer Res. 2007 Sep 1;67(17):8180–8187.
   PubMed Web of Science ®Google Scholar
• Higashi T, Hayashi H, Kitano Y, et al. Statin attenuates cell proliferative ability via TAZ (WWTR1) in hepatocellular carcinoma. Med Oncol. 2016 Nov;33(11):123.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Sakamoto Y, Ito D, et al. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. Biosci Trends. 2017 Nov 20;11(5):574–580.
   PubMed Web of Science ®Google Scholar
• Zhou T-Y, Zhuang L-H, Hu Y, et al. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells. Sci Rep. 2016 Aug 01 online;6:30483.
   PubMed Web of Science ®Google Scholar
• Zhou YY, Zhu GQ, Wang Y, et al. Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget. 2016 Apr 19;7(16):21753–21762.
   PubMed Web of Science ®Google Scholar
• Bergen WG, Mersmann HJ. Comparative aspects of lipid metabolism: impact on contemporary research and use of animal models. J Nutr. 2005 Nov;135(11):2499–2502.
   PubMed Web of Science ®Google Scholar